Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alternating Bendamustine/Rituximab and Cytarabine/Rituximab for Untreated Mantle Cell Lymphoma
NCT02728531Phase 1Completed
- Sponsor
- Washington University School of Medicine
- Start
- Apr 2016
- Primary completion
- Jan 2019
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bendamustine, cytarabine and rituximab in mantle cell lymphoma (MCL), sponsored by Washington University School of Medicine. Primary endpoint: Stem cell mobilization success rate at 25 weeks. Started Apr 2016; status: completed.
02
Drugs
bendamustinecytarabinerituximab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT02728531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02728531.